We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

169 hedge funds and large institutions have $790M invested in Ariad Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

19% more call options, than puts

Call options by funds: $31.5M | Put options by funds: $26.5M

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

7% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 29

1% less funds holding

Funds holding: 171169 (-2)

10% less capital invested

Capital invested by funds: $877M → $790M (-$86.6M)

Holders
169
Holders Change
-2
Holders Change %
-1.17%
% of All Funds
4.86%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
27
Increased
63
Reduced
44
Closed
29
Calls
$31.5M
Puts
$26.5M
Net Calls
+$5.02M
Net Calls Change
+$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$1.98M +$1.35M +196,399 +173%
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
$1.92M -$239K -34,700 -10%
Zurich Cantonal Bank
53
Zurich Cantonal Bank
Switzerland
$1.91M +$688K +100,000 +50%
State Board of Administration of Florida Retirement System
54
State Board of Administration of Florida Retirement System
Florida
$1.87M -$13.8K -2,005 -0.7%
PI
55
Putnam Investments
Massachusetts
$1.72M +$4.66K +677 +0.3%
JG
56
Jefferies Group
New York
$1.64M +$1.27M +184,702 +253%
Citadel Advisors
57
Citadel Advisors
Florida
$1.57M -$3.23M -469,018 -66%
IG
58
ING Group
Netherlands
$1.56M +$80.8K +11,750 +5%
EEG
59
E.E. Geduld
$1.56M -$224K -32,500 -12%
TA
60
Teachers Advisors
New York
$1.49M +$810K +117,817 +102%
Lazard Asset Management
61
Lazard Asset Management
New York
$1.44M +$1.55M +225,800 New
NI
62
Numeric Investors
Massachusetts
$1.31M +$587K +85,400 +71%
JGC
63
J. Goldman & Co
New York
$1.31M +$1.41M +205,000 New
ProShare Advisors
64
ProShare Advisors
Maryland
$1.28M +$353K +51,269 +34%
Swiss National Bank
65
Swiss National Bank
Switzerland
$1.25M -$61.2K -8,900 -4%
ACPU
66
Arrowgrass Capital Partners (US)
Delaware
$1.23M +$1.32M +192,500 New
HCM
67
Highbridge Capital Management
New York
$1.2M +$1.29M +188,100 New
SC
68
Selz Capital
New York
$1.15M -$1.51M -220,000 -55%
SC
69
Skylands Capital
Wisconsin
$1.08M +$119K +17,250 +11%
DCC
70
Dow Chemical Company
Michigan
$1.02M +$241K +35,000 +28%
NCMW
71
Northern Capital Management (Wisconsin)
Wisconsin
$946K +$934K +135,850 +1,078%
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$904K -$10.5K -1,526 -1%
American Century Companies
73
American Century Companies
Missouri
$892K +$963K +139,960 New
BA
74
BlackRock Advisors
Delaware
$886K +$734K +106,681 +329%
Millennium Management
75
Millennium Management
New York
$871K -$783K -113,800 -45%

ARIA Hedge Fund Activity: Q2 2014 in Review

169 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q2 2014, worth a combined $790M — down 9.9% from $877M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ARIA and 27 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 63 added.

The largest buyer was AQR Capital Management, adding an estimated $20.4M. The largest seller was Slate Path Capital, exiting entirely with an estimated $53.4M sold.

  • 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q2 2014, down from 171 in Q1 2014.
  • Funds reported $790M of Ariad Pharmaceuticals Inc stock for Q2 2014, down 9.9% quarter-over-quarter.
  • 27 funds opened new Ariad Pharmaceuticals Inc positions in Q2 2014 and 29 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q2 2014 was AQR Capital Management, an estimated $20.4M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q2 2014 was Slate Path Capital, an estimated $53.4M sold.

Based on aggregated 13F filings for Q2 2014.